ArticleJournal of patient-reported outcomes2025
Development and validation of a patient-reported-experience measure to ascertain treatment satisfaction in migraine: the MISAT-Q questionnaire.
Article in Journal of patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe patient's perspective is increasingly relevant in health decision making. In daily practice, care of patients with migraine should include evaluation of their satisfaction with acute and preventive treatments, the interference with daily living, as well as with the care received by the healthcare team. The aim was to develop and validate a novel specific self-reported patient-reported-experience measure (PREM) in Spanish (Spain), to ascertain satisfaction with migraine treatment; the MISAT-Q questionnaire. METHODOLOGY: A multicenter, crosssectional, non-interventional study was conducted between June 2023 and March 2024 in headache units in Spain. Patients with migraine currently receiving treatment were included. A 35-items preliminary instrument was developed after literature review and cognitive debriefing with experts and patients. Three samples were used: a) 23 patients to assess feasibility/pertinence of items; b) 158 patients for item reduction; and c) 209 patients for validation of PREM. Measures for concept validity included Patient Global Impression of change (PGI), Headache Impact Scale-6 items (HIT-6), and Health-Related Quality-of-life (EQ-5D-3 L). Feasibility, reliability and validity (content, discriminant, construct, and concurrent) were assessed.
resultsFeasibility: face value (good acceptance to answer the questionnaire), administration time (below 10 minutes), floor and ceiling effects (below 40% in any extreme response category), percentage of missing values in each item (below 20%) was found in the validation sample. Factor analysis item reduction resulted in a 22-item questionnaire with 7 dimensions: undesirable side effects, treatment effectiveness in crisis and in prevention, convenience-of-use, impact on daily activities, medical care, and global satisfaction, supported with confirmatory factor analysis: CFI = 0.983; TLI = 0.980; χ
conclusionsThe MISAT-Q questionnaire is a well-accepted, reliable and valid measure of migraine treatment satisfaction in Spanish. Responsiveness attribute needs to be explored. This novel PREM may facilitate clinicians when making health decision in the treatment management of patients with migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.